Clarification – TruScreen Interim Results – SalesTimeline

NZX and Media Release 14 December, 2017
NZX Limited
WELLINGTON


TRUSCREEN INTERIM RESULTS TO 30 SEPTEMBER 2017
Clarification
Timing of sales for Financial Year Ending 31 March, 2018

TruScreen wishes to clarify the statement made in its results announcement today regarding the
timing of the increase in sales.

The reference to the ‘final quarter of FY18’ refers to the final quarter of the financial year ending 31
March, 2018. That is, January to March, 2018.



ENDS
For more information visit www.truscreen.com or contact:
Martin Dillon
TruScreen Chief Executive Officer
Email: martindillon@truscreen.com
Media Liaison
Jackie Ellis
Email: jackie@ellisandco.co.nz
Phone: +64 27 246 2505

About TruScreen:
TruScreen’s real time cervical cancer technology
utilises a digital wand which is placed on the
surface of the cervix to measure electrical and
optical signals from the surrounding tissue. A
sophisticated proprietary algorithm framework
distinguishes between normal and abnormal
(cancerous and precancerous) tissue to identify
precancerous change, or cervical intraepithelial
neoplasia (CIN). A Single Use Sensor (SUS) is used
for each patient to protect against cross-infection.